NVO PE Ratio & Valuation, Is NVO Overvalued

Historical Valuation

Novo Nordisk A/S (NVO) is now in the Undervalued zone, suggesting that its current forward PE ratio of 15.05 is considered Undervalued compared with the five-year average of 27.87. The fair price of Novo Nordisk A/S (NVO) is between 59.61 to 89.44 according to relative valuation method. Compared to the current price of 38.66 USD , Novo Nordisk A/S By Undervalued By 35.14%.

Relative Value

Fair Zone

59.61-89.44

Current Price：38.66

35.14%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Novo Nordisk A/S (NVO) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Novo Nordisk A/S (NVO) has a current Price-to-Book (P/B) ratio of 8.73. Compared to its 3-year average P/B ratio of 26.07, the current P/B ratio is approximately -66.49% higher. Relative to its 5-year average P/B ratio of 24.90, the current P/B ratio is about -64.92% higher. Novo Nordisk A/S (NVO) has a Forward Free Cash Flow (FCF) yield of approximately 4.50%. Compared to its 3-year average FCF yield of 2.90%, the current FCF yield is approximately 54.83% lower. Relative to its 5-year average FCF yield of 3.12%, the current FCF yield is about 43.98% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for NVO competitors is 7.02, providing a benchmark for relative valuation. Novo Nordisk A/S Corp (NVO.N) exhibits a P/S ratio of 4.79, which is -31.83% above the industry average. Given its robust revenue growth of 0.69%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of NVO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of NVO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is NVO currently overvalued or undervalued?

What is Novo Nordisk A/S (NVO) fair value?

NVO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Novo Nordisk A/S (NVO) is between 59.61 to 89.44 according to relative valuation method.

How does NVO's valuation metrics compare to the industry average?

The average P/S ratio for NVO's competitors is 7.02, providing a benchmark for relative valuation. Novo Nordisk A/S Corp (NVO) exhibits a P/S ratio of 4.79, which is -31.83% above the industry average. Given its robust revenue growth of 0.69%, this premium appears unsustainable.

What is the current P/B ratio for Novo Nordisk A/S (NVO) as of Mar 11 2026?

As of Mar 11 2026, Novo Nordisk A/S (NVO) has a P/B ratio of 8.73. This indicates that the market values NVO at 8.73 times its book value.

What is the current FCF Yield for Novo Nordisk A/S (NVO) as of Mar 11 2026?

As of Mar 11 2026, Novo Nordisk A/S (NVO) has a FCF Yield of 4.50%. This means that for every dollar of Novo Nordisk A/S's market capitalization, the company generates 4.50 cents in free cash flow.

What is the current Forward P/E ratio for Novo Nordisk A/S (NVO) as of Mar 11 2026?

As of Mar 11 2026, Novo Nordisk A/S (NVO) has a Forward P/E ratio of 15.05. This means the market is willing to pay $15.05 for every dollar of Novo Nordisk A/S's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Novo Nordisk A/S (NVO) as of Mar 11 2026?

As of Mar 11 2026, Novo Nordisk A/S (NVO) has a Forward P/S ratio of 4.79. This means the market is valuing NVO at $4.79 for every dollar of expected revenue over the next 12 months.

NVO Valuation